Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.

ABSTRACT:

Background

Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-resistant bipolar depression (TRBD) do not respond.

Objectives

This study aimed to identify clinical and sociodemographic characteristics that are associated with nonresponse of anhedonia following short-term ketamine treatment in TRBD.

Design

A retrospective analysis using data from two naturalistic, observational registries of 31 patients with TRBD and baseline anhedonia (Snaith-Hamilton Pleasure Scale (SHAPS) > 2). Patients received eight doses of ketamine (IV: 0.5 mg/kg; oral: 2.0-2.5 mg/kg) over a short-term treatment course.

Methods

Patients were classified as responders or nonresponders based on a ⩾50%

SUBMITTER: Kachlik Z 

PROVIDER: S-EPMC12861376 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature